Digital pathology technology presents initial economic challenges, but its potential to generate valuable data could offset costs, as highlighted by Derek Welch of PathGroup. The US lacks incremental reimbursement for digital pathology, prompting labs to explore partnerships, particularly in oncology, where pixelated images can enhance drug development and facilitate real-world data generation. As current digitization rates are low, labs positioned within a digital network could significantly contribute to pharma collaborations, harnessing AI to streamline diagnostics and improve patient outcomes.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
